Dr. Justin Favaro, MD
Claim this profileOncology Specialists of Charlotte
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
5 reported clinical trials
7 drugs studied
Area of expertise
1Lung Cancer
Stage IV
Stage III
EGFR negative
2Non-Small Cell Lung Cancer
Stage IV
Stage III
EGFR negative
Affiliated Hospitals
Clinical Trials Justin Favaro, MD is currently running
Tetrodotoxin
for Chemotherapy-Induced Neuropathic Pain
To be eligible for the trial, subjects must have ongoing moderate to severe neuropathic pain related to a prior course of platinum and/or taxane chemotherapy and have no clinical evidence of actively progressive disease. The trial period will comprise a Screening Period (up to 35 Days), a two-week period for the determinations of Baseline pain followed by randomization and 4-day treatment, followed by a 12-week follow up period (12 weeks total after initial treatment), and an End-of-Trial/Follow-up visit, which will occur at Week 13. This is a study to research the effects of the study drug on neuropathic pain compared placebo.
Recruiting0 awards Phase 211 criteria
TTFields + Pembrolizumab
for Lung Cancer
This is a multicenter, randomized, open-label study of Tumor Treating Fields (TTFields) at 150 kHz to the thorax using the NovoTTF-200T System with IV pembrolizumab in subjects previously untreated for advanced or metastatic, PD-L1 positive non-small cell lung cancer (NSCLC). The primary objective is to evaluate the progression-free survival (PFS) by RECIST 1.1 in subjects with TPS ≥1 percent, 1L metastatic/current advanced NSCLC treated with TTFields concomitant with pembrolizumab compared to those treated with pembrolizumab alone. The device is an experimental, portable, battery operated device for chronic administration of alternating electric fields (termed TTFields) to the region of the malignant tumor, by means of surface, insulated electrode arrays.
Recruiting1 award Phase 28 criteria
More about Justin Favaro, MD
Clinical Trial Related3 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Justin Favaro, MD has experience with
- NovoTTF-200T
- Panobinostat
- NovoTTF-100L
- Single Cycle Tetrodotoxin
- Niraparib
- Pembrolizumab
Breakdown of trials Justin Favaro, MD has run
Lung Cancer
Non-Small Cell Lung Cancer
Multiple Myeloma
Plasma Cell Neoplasms
Peripheral Neuropathy
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Justin Favaro, MD specialize in?
Justin Favaro, MD focuses on Lung Cancer and Non-Small Cell Lung Cancer. In particular, much of their work with Lung Cancer has involved Stage IV patients, or patients who are Stage III.
Is Justin Favaro, MD currently recruiting for clinical trials?
Yes, Justin Favaro, MD is currently recruiting for 2 clinical trials in Charlotte North Carolina. If you're interested in participating, you should apply.
Are there any treatments that Justin Favaro, MD has studied deeply?
Yes, Justin Favaro, MD has studied treatments such as NovoTTF-200T, Panobinostat, NovoTTF-100L.
What is the best way to schedule an appointment with Justin Favaro, MD?
Apply for one of the trials that Justin Favaro, MD is conducting.
What is the office address of Justin Favaro, MD?
The office of Justin Favaro, MD is located at: Oncology Specialists of Charlotte, Charlotte, North Carolina 28204 United States. This is the address for their practice at the Oncology Specialists of Charlotte.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.